Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

ARRY: New 8K irt Genentech agreement. Expansion to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ThomasS Member Profile
 
Followed By 12
Posts 2,362
Boards Moderated 0
Alias Born 05/05/05
160x600 placeholder
U.S., Mexico Strike Deal to Scrap Sugar Duties
The U.S. and Mexico have struck a deal to scrap tariffs on imports of Mexican sugar, ending a trade dispute that rattled candy-makers over higher costs for their key ingredient.
Deezer Names New CEO Before Full U.S. Launch
Whistleblowers Score a Big Payday -- Update
Mobile's Rise Poses a Riddle for Banks
AT&T Boosts Dividend
U.S. Hot Stocks: Hot Stocks to Watch
Brazilian Shares Rise, Led by Rossi Residencial; Real Weakens Slightly
Oracle Beats Street View for First Time in a Year
Ally Financial Exits TARP as Treasury Sells Remaining Stake -- 3rd Update
Liberty Media's CommerceHub Acquires E-Commerce Adviser Mercent
ThomasS   Monday, 09/08/08 07:36:58 AM
Re: None
Post # of 184916 
ARRY: New 8K irt Genentech agreement. Expansion to include a new target under the existing collaboration #msg-29627295:

Array BioPharma Inc. (the "Company") and Genentech, Inc. ("Genentech") have entered into an amendment effective as of September 1, 2008 (the "Amendment") to the Drug Discovery Collaboration Agreement between the Company and Genentech dated December 22, 2003, as amended (the "Agreement"). Under the Amendment, the Company and Genentech added a new collaboration target and agreed to increase the number of the Company's full-time equivalent scientists ("FTEs") performing services under the Agreement. Genentech continues to have the right to reduce the number of FTEs under the Agreement after January 1, 2010, subject to higher minimum levels set forth in the Amendment. The Amendment also provides for the payment of a one-time license fee, research funding and milestone payments to the Company in connection with the new target.

"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist